POM-V Prescription Required

Veteglan 0.075 mg/ml Solution for Injection for Cows, Sows and Mares

Active ingredient: d-Cloprostenol

Form

Injection

Species

Cattle Horses Pigs

Manufacturer

Laboratorios Calier, SA

VMD MA No.

20634/3002

What it's used for

• • • • of GnRH or analogue) Sows • Mares •

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for d-Cloprostenol

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Veteglan 0.075 mg/ml Solution for Injection for Cows, Sows and Mares — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

•
•
•
•
of GnRH or analogue)
Sows
•
Mares
•

Cows: 2 ml of the product / animal (equivalent to 150 µg d-Cloprostenol /animal)
Induction of oestrus (also in cows showing weak or silent heat): Administer the product
after determination of the presence of a functional (6
th
to 18
th
day of
cycle). Heat usually appears within 48-60 hours. Proceed to insemination 72-96h after
treatment. If there is no sign of oestrus, the treatment may be repeated 11 days after
the first injection.
Induction of parturition: administer the product after the 270
th
day of gestation.
Parturition usually takes place within 30-60 hours after treatment.
Synchronisation of oestrus: administer the product twice (within an interval of 11 days).
Proceed with inseminations 72h and 96 h after the second injection.
Ovarian dysfunction: administer the product after determination of presence of the
corpus luteum. Then, proceed to inseminate at the first oestrus after injection. If oestrus
does not take place, conduct a further gynaecological examination, and repeat the
injection 11 days after the first administration. Insemination must always be carried out
72-96 hours after injection.
Clinical endometritis with the presence of a functional corpus luteum, pyometra:
administer one dose of the product. If necessary, repeat the treatment after 10 days.
Mummified foetus: Administer one dose of the product. Expulsion of the foetus is
observed within 3-4 days after administration of the product.
Induction of abortion: administer one dose of the product in the first half of pregnancy.
Delayed uterine involution:
out one or two further treatments (within an interval of 24 hours).
Therapy for the treatment of ovarian cysts (9-14 days after initial administration of
GnRH or analogue): administer the product 9-14 days after verifying the positive
response to treatment with GnRH or analogue.
Sows:
Mares:
The rubber stopper of the vial can be safely punctured up to 10 times. Otherwise, for the
20 ml vials automatic syringe equipment, or a suitable draw-off needle, should be used
to prevent excessive puncture of the closure.

Do not use in pregnant animals unless it is desirable to induce parturition or interruption
of pregnancy.
Do not use in animals with spastic dysfunctions of the gastrointestinal tract and/or
respiratory system.
Do not use in cows or sows who may have a dystocic parturition due to abnormal
position of a foetus, mechanical obstruction, etc.
Do not use in animals suffering cardiovascular or respiratory diseases.
Do not use by intravenous route.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.

Target species: Cows
Undetermined frequency:Injection site anaerobic infection (swelling and
crepitus)
Retained placenta
1
Anaerobic infection is common if anaerobic bacteria penetrate the tissue of the
infection site. This applies especially to intramuscular injection and in particular to
cows.
Depending on the timing of treatment relative to the date of conception, the
placental retention rate can be increased when used for induction of parturition.
Target species: Sows
Undetermined frequency:Injection site anaerobic infection (swelling and
crepitus)
Retained placenta
Behavioural changes
1
Anaerobic infection is common if anaerobic bacteria penetrate the tissue of the
infection site. This applies especially to intramuscular injection and in particular to
cows.
Depending on the timing of treatment relative to the date of conception, the
placental retention rate can be increased when used for induction of parturition
Behavioural changes occur after treatment for induction of farrowing which are
similar to those changes associated with natural farrowing and usually cease within 1
hour.
Target species: Mares
Undetermined frequency:Injection site anaerobic infection (swelling and
crepitus)
Retained placenta
Sweating
3,4
Increased respiratory rate
Increased heart rate
Abdominal discomfort
, diarrhoea
4,5
Depression
.
Anaerobic infection is common if anaerobic bacteria penetrate the tissue of the
infection site. This applies especially to intramuscular injection and in particular to
cows.
Depending on the timing of treatment relative to the date of conception, the
placental retention rate can be increased when used for induction of parturition
Occurring within 20 minutes of treatment.
When exceptionally high doses are given and are usually mild and transient.
Watery
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See also the last section of the
package leaflet for respective contact details.

The response of cows to the synchronisation protocols is not homogeneous between
herds, nor within the same herd, and may vary depending on the physiological state of
the animal at the time of treatment (sensitivity and a functional state of the
age, physical condition, interval from calving, etc.).

Special precautions for safe use in the target species
Induction of parturition and abortion may increase the risk of complications, retained
placenta, foetal death and metritis.
To reduce the risk of anaerobic infections, which might be related to the pharmacological
properties of prostaglandins, care should be taken to avoid injection through
contaminated areas of skin. Clean and disinfect injection sites thoroughly before
administration.
In case of oestrus induction in cows: from the 2
nd
day after injection, adequate heat
detection is necessary.
Induction of parturition in sows before day 114 of gestation may result in an increased
risk of stillbirths and the need for manual assistance at farrowing.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
Prostaglandins of the F2
bronchospasm or miscarriage.
Take care to avoid self-injection or skin contact when handling the product.
Pregnant women, women of child-bearing age, asthmatics and people with bronchial or
other respiratory problems, should avoid contact with, or wear disposable impervious
gloves when administering the product.
Accidental spillage on the skin should be washed off immediately with soap and water.
In case of accidental self-injection or shortness of breath resulted from accidental
inhalation or injection seek medical advice immediately and show the package leaflet or
label to the physician.
Do not eat, drink or smoke while handling the product.
Special precautions for the protection of the environment:
Not applicable.

Do not store above 25ºC
Keep the vial in the outer carton in order to protect from light

Cattle: meat and offal: zero days
milk: zero hours
Pigs: meat and offal: 1 day
Horses: meat and offal: 2 days
milk: zero hours

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.